These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36061236)

  • 1. Erratum: Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis [Corrigendum].
    J Hepatocell Carcinoma; 2022; 9():853-854. PubMed ID: 36061236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis.
    Aydin Y; Koksal AR; Thevenot P; Chava S; Heidari Z; Lin D; Sandow T; Moroz K; Parsi MA; Scott J; Cohen A; Dash S
    J Hepatocell Carcinoma; 2021; 8():1579-1596. PubMed ID: 34917553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection [Corrigendum].
    J Hepatocell Carcinoma; 2021; 8():1297-1298. PubMed ID: 34737984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Identification and Analysis of the Blood lncRNA Signature for Liver Cirrhosis and Hepatocellular Carcinoma.
    Xia Q; Shu Z; Ye T; Zhang M
    Front Genet; 2021; 12():692400. PubMed ID: 34276793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
    Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
    Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of detection of serum glypican-3 level in diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma].
    Wang YY; Zhou CJ; Li J; Zhou L; Li MS; Xiao B
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Aug; 37(8):1060-1065. PubMed ID: 28801286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erratum: Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum].
    Cancer Manag Res; 2020; 12():4169-4170. PubMed ID: 32581588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum].
    J Inflamm Res; 2021; 14():4601-4602. PubMed ID: 34548805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: miR-500a-3p is a Potential Prognostic Biomarker in Hepatocellular Carcinoma [Corrigendum].
    Int J Gen Med; 2022; 15():2215-2216. PubMed ID: 35250299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erratum: Downregulation of CENPK Suppresses Hepatocellular Carcinoma Malignant Progression through Regulating YAP1 [Corrigendum].
    Onco Targets Ther; 2022; 15():1143-1145. PubMed ID: 36238137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum: Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum].
    Cancer Manag Res; 2021; 13():2515. PubMed ID: 33776476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum: Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum].
    Cancer Manag Res; 2021; 13():8353-8354. PubMed ID: 34795522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum: Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma [Corrigendum].
    Cancer Manag Res; 2020; 12():6861-6862. PubMed ID: 32848458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum].
    Onco Targets Ther; 2020; 13():12253-12254. PubMed ID: 33273830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population [Corrigendum].
    Pharmgenomics Pers Med; 2021; 14():1715-1716. PubMed ID: 35002289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.
    Hu X; Bao M; Huang J; Zhou L; Zheng S
    Front Oncol; 2020; 10():617539. PubMed ID: 33330112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
    Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
    Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum: Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo [Corrigendum].
    Onco Targets Ther; 2020; 13():5707. PubMed ID: 32606782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erratum: miR-221 Suppression Through Nanoparticle-Based miRNA Delivery System for Hepatocellular Carcinoma Therapy and Its Diagnosis as a Potential Biomarker [Corrigendum].
    Int J Nanomedicine; 2020; 15():8293-8294. PubMed ID: 33149576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erratum: GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma [Corrigendum].
    Int J Nanomedicine; 2022; 17():3073-3074. PubMed ID: 35855749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.